Showing results (11-20 of 125) with videos related to

Sort By:
Pageof 13
Molecular Cancer Therapeutics|January 13, 2012
MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cellsChin-Tung Chen, Hyaehwan Kim, David Liska, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 19, 2007
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacyJohn M L Ebos, Christina R Lee, James G Christensen, et al.
Neuro-Oncology|July 12, 2007
Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastomaSophie de Boüard, Paulette Herlin, James G Christensen, et al.
Cancer Research|January 27, 2011
Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitorsJie Qi, Michele A McTigue, Andrew Rogers, et al.
Molecular Cancer Therapeutics|June 16, 2005
Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitorJames G Christensen, Patrick W Vincent, Wayne D Klohs, et al.
Cancer Cell|March 3, 2009
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesisJohn M L Ebos, Christina R Lee, William Cruz-Munoz, et al.
Cell Cycle (Georgetown, Tex.)|July 2, 2011
Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumabLori S Hart, Nathan G Dolloff, David T Dicker, et al.
Cell Reports|December 28, 2018
A Transient Pseudosenescent Secretome Promotes Tumor Growth after Antiangiogenic Therapy WithdrawalMichalis Mastri, Amanda Tracz, Christina R Lee, et al.
BMC Cancer|November 27, 2009
PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cellsHal E Crosswell, Anindya Dasgupta, Carlos S Alvarado, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 2, 2011
Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse modelsShinji Yamazaki, Paolo Vicini, Zhongzhou Shen, et al.
Pageof 13